Injective news: 21Shares files for a new INJ ETF

• 21Shares has filed for a new spot Injective (INJ) ETF with the US Securities and Exchange Commission.
• The ETF issuer submitted the application on October 20, 2025, making Injective one of the altcoins with multiple ETF applications before the SEC.
• INJ trades at $8.75 as cryptocurrencies look to bounce off recent lows amid ETF-fueled bullish sentiment.

21Shares, a leading issuer of cryptocurrency exchange-traded products, has submitted a new filing for a spot exchange-traded fund (ETF) to the US Securities and Exchange Commission.

The price of Injective’s native token INJ saw a slight uptick amid the development, with bulls holding above the $8.00 level.

21Shares files for a new injective spot ETF

Injective’s official X account shared news of 21Shares’ INJ ETF filing with SEC on Monday.

Per the filing, the proposed 21Shares Injective ETF aims to provide investors with direct exposure to INJ.

Like other proposed listings, and following in the inaugural launches of Bitcoin and Ethereum spot ETFs, the 21Shares Injective ETF is an exchange-traded fund that will hold physical INJ tokens in cold storage custody.

“This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress,” the Injective team posted on X.

Injective is one of the top 100 cryptocurrencies and its growth across the industry comes amid traction for sectors such as decentralized finance and real-world assets.

Recently, the layer-1 project held its inaugural meeting of the Injective Council.

The platform’s growing presence and adoption gets notable boost from industry leaders helping to champion key strategic roadmap goals, including native Ethereum Virtual Machine, digital asset treasury, INJ ETFs and pre-IPO markets.

Major partners include Google Cloud, T-Mobile, Deutsche Telekom, YZi Labs, Galaxy Digital and BitGo.

Previously Canary Capital had submitted for an INJ ETF in July.

Injective is a high-performance Layer 1 blockchain engineered for decentralized financial services (DeFi).

The platform is capable of processing more than 25,000 transactions per second and utilizes its native token, INJ, to secure the network via a delegated proof-of-stake (DPoS) consensus mechanism.

The blockchain tackles infrastructure challenges such as fragmented liquidity and slow transaction finality by integrating exchange primitives with CosmWasm-based composability, while Comet BFT (formerly Tendermint BFT) ensures fast finality.

INJ price outlook as ETF approval hype boosts sentiment

As noted, INJ traded near $8.75 amid broader crypto volatility.

While the token’s price did not explode amid the ETF news, enthusiasm is high across the market.

The upbeat outlook is mostly down to anticipation that the SEC is set to greenlight multiple crypto ETFs and current market downside pressure could dissipate to see bulls take over.

The Injective price is down from its December 2024 peak near $35 and well off the all-time high of $52.75 reached in March 2024.

However, bulls are looking to hold above $8.00 after dipping to around $7.80 following the dip on October 17, 2025.

Prior to this, INJ had shown resilience after bouncing off lows of $6.90 in April.

Apart from ETF-driven sentiment, treasury asset bets such as the $100 million move by Pineapple Financial, help bulls.

The post Injective news: 21Shares files for a new INJ ETF appeared first on CoinJournal.